BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu X, Naseri A, Houbraken J, Akbari F, Wang X, Zhao R, Zhang H, Najafzadeh MJ, Deng S. Identification and in vitro antifungal susceptibility of causative agents of onychomycosis due to Aspergillus species in Mashhad, Iran. Sci Rep 2021;11:6808. [PMID: 33762586 DOI: 10.1038/s41598-021-86038-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ghobadi E, Saednia S, Emami S. Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114161] [Reference Citation Analysis]
2 Pakshir K, Kamali M, Nouraei H, Zomorodian K, Motamedi M, Mahmoodi M. Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis. Sci Rep 2021;11:20736. [PMID: 34671053 DOI: 10.1038/s41598-021-00104-0] [Reference Citation Analysis]
3 Nargesi S, Jafarzadeh J, Najafzadeh MJ, Nouripour-Sisakht S, Haghani I, Abastabar M, Ilkit M, Hedayati MT. Molecular identification and antifungal susceptibility of clinically relevant and cryptic species of Aspergillus sections Flavi and Nigri. J Med Microbiol 2022;71. [PMID: 35451946 DOI: 10.1099/jmm.0.001480] [Reference Citation Analysis]
4 Silva-Neves V, Hugo V, Alves P, Amado JC, Pais-Vieira C, Sousa F, Cerqueira F, Pinto E, Pais-Vieira M. Quality of life and therapeutic regimen management in onychomycosis patients and in vitro study of antiseptic solutions. Sci Rep 2021;11:12789. [PMID: 34140577 DOI: 10.1038/s41598-021-92111-4] [Reference Citation Analysis]